Diffusing Alpha-emitters Radiation Therapy: In vivo Measurements of Effective Diffusion and Clearance Rates Across Multiple Tumor Types

Mirta Dumančić^{1,*,†}, Guy Heger^{1,*}, Ishai Luz², Maayan Vatarescu², Noam Weizman^{1,3}, Lior Epstein^{1,4}, Tomer Cooks^{2,‡}, Lior Arazi^{1,‡}

¹Unit of Nuclear Engineering, Faculty of Engineering Sciences, Ben-Gurion University of the Negev, P.O.B. 653 Be'er-Sheva 8410501, Israel

² The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Be'er Sheva, Israel

³ Radiation Therapy Unit, Oncology Department, Hadassah Medical Center, Jerusalem 91120, Israel

⁴ Radiation Protection Department, Soreq Nuclear Research Center, Yavne, Israel * These authors contributed equally

[†] Current affiliation: Medical Physics Unit, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada

Version typeset March 13, 2025

[‡] Authors to whom correspondence should be addressed. Lior Arazi: larazi@bgu.ac.il, Tomer Cooks: cooks@bgu.ac.il

Abstract

Background: Diffusing alpha-emitters radiation therapy ("Alpha-DaRT") is a new modality that uses alpha particles to treat solid tumors. Alpha-DaRT employs interstitial sources loaded with low activities of 224 Ra, which release a chain of short-lived alpha-emitters diffusing over a few millimeters around each source. Alpha-DaRT dosimetry is described, to first order, by a framework called the "diffusion-leakage" (DL) model.

Purpose: The aim of this work is to estimate the tumor-specific parameters of the DL model from *in vivo* studies on multiple histological cancer types.

Methods: Autoradiography studies with phosphor imaging were conducted on 113 mice-borne tumors from 10 cancer cell lines. An observable, referred to as the "effective diffusion length" L_{eff} , was extracted from images of histological slices obtained using phosphor screens. The tumor and Alpha-DaRT source activities were measured after excision with a gamma counter to estimate the probability of ²¹²Pb clearance from the tumor by the blood, $P_{leak}(Pb)$.

Results: The measured values of L_{eff} are in the range of 0.2-0.7 mm across different tumor types and sizes. $P_{leak}(Pb)$ is between 10–90% for all measured tumors and it generally decreases in magnitude and spread for larger tumors.

Conclusions: The measured values of L_{eff} and $P_{leak}(Pb)$ and associated dose calculations indicate that hexagonal Alpha-DaRT source lattices of ~ 4 mm spacing with μ Ci-scale ²²⁴Ra activities can lead to effective coverage of the tumor volume with therapeutic dose levels, with considerable margin to compensate for local variations in diffusion and leakage.

Keywords: DaRT, Targeted Alpha Therapy, alpha-radiopharmaceutical therapy, alpha dose calculations, brachytherapy.

1 Introduction

Alpha particles are of great interest for radiotherapy due to their high relative biological effectiveness (RBE), their efficacy against hypoxic cells, and the potential for sparing healthy tissue ¹. Multiple preclinical and clinical studies are underway in targeted alpha-therapy (TAT)^{2,3,4,5,6} with ²²³RaCl₂ already FDA-approved for clinical use against bone metastases in castration-resistant prostate cancer^{7,8,9,10}. Despite their benefits, the short range of alpha particles has largely hindered their clinical use against solid tumors. Only recently, clinical trials using PSMA-TAT¹¹ have begun showing successful results against macroscopic metastases.

A different approach for treating solid tumors with alpha radiation is *diffusing alpha-emitters radiation therapy* ("Alpha-DaRT")¹². Alpha-DaRT is based on intratumoral insertion of sources loaded with a few μ Ci of radium-224 (²²⁴Ra, $t_{1/2} = 3.63$ d), that continuously release from their surface a chain of short-lived alpha- and beta–emitting atoms (²²⁰Rn, ²¹⁶Po, ²¹²Pb, ²¹²Bi, ²¹²Po and ²⁰⁸Tl). Those daughter atoms spread throughout the tumor by diffusion and (potentially) vascular and interstitial convection, creating a therapeutic region of several mm in diameter around each source through their alpha decays and so overcoming the short-range limitation of alpha particles¹². Alpha-DaRT has been studied *in vitro* and *in vitro* and *in vitro* as a stand-alone treatment ^{12,13,14,15,16,17} and in combination with chemotherapy ^{18,19,20,21} and immunotherapy ^{22,23,24,25,26,27,28,29}. However, no systematic study has been conducted so far to compare the physics properties of Alpha-DaRT treatment across various histological cancer types.

In the first clinical trial on locally advanced and recurrent squamous cell carcinoma (SCC) of the skin and head and neck³⁰, all treated tumors showed a positive response (30– 100% shrinkage in their longest dimension) and nearly 80% displayed complete response. The Alpha-DaRT source 224 Ra activity of 2 μ Ci/cm and nominal spacing of 5 mm between the sources were selected based on dose calculations performed by an approximate theoretical approach—the "diffusion-leakage" (DL) model^{31,32,33}. The calculations relied on preliminary estimates for the DL model parameters for SCC, derived from autoradiography experiments on such tumors in mice³¹ and aimed to cover the tumor volume with a minimal alpha dose of 10 Gy. A following pilot study in the US, on patients with recurrent or unresectable skin cancer (SCC and basal cell carcinoma), employed sources of 3 μ Ci/cm and nominal spacing of 4 mm, reporting 100% complete response at 12 weeks following treatment (with 90% confirmed by CT)? A more recent publication, summarizing a pooled analysis of 81 treated head and neck or skin tumors from four clinical trials with a median follow-up of 14 months, reported a complete response in 89% of the treated lesions, a two-year local recurrence-free survival of 77%, and no grade 2 or higher late toxicities 34 . With more clinical trials underway (e.g., for pancreatic cancer³⁵), there is a need to estimate the DL model parameters in additional tumor types to recommend a plausible starting point for treatment planning in terms of source activity and spacing. Different tumor models offer various conditions of the tumor microenvironment and tissue perfusion (e.g., blood flow, blood volume, mean transit time) that can be expected to affect the relevant DL model parameters³⁶. Cell-type specific DNA repair rates and immunogenic factors can all contribute to a variable rate of cell death in each tumor model and hence cause different levels of necrosis in the tumor.

In this study, we report on results from a systematic campaign of *in vivo* experiments with Alpha-DaRT treatment in 113 mice tumors across 10 different cell lines, including breast cancer, prostate cancer, pancreatic cancer, and colorectal cancer cell lines. The experiments were done after 4–5 days of treatment when all daughter atoms are in secular equilibrium with ²²⁴Ra, mirroring the situation in real-life clinical trials. A recently published study ³⁷ focused on measuring diffusion properties for short source dwelling times, where only ²²⁰Rn and ²¹⁶Po are in secular equilibrium with ²²⁴Ra. The two complementary studies combined provide an experimental basis—albeit limited to mice—for suggesting a reasonable starting point for treatment planning in future Alpha-DaRT clinical trials for different tumor indications.

2 Methods

2.1 The Diffusion-Leakage model in equilibrium

In a previously published work³¹, it was shown that the two most important parameters governing the spread of activity inside the tumor are the diffusion lengths of ²²⁰Rn and ²¹²Pb, L_{Rn} and L_{Pb} . In a recently published first estimate of L_{Rn} in 24 mice-borne subcutaneous tumors with five different cell lines³⁷, the source dwelling time inside the tumor was kept to 30 min, thus preventing the buildup of ²¹²Pb. The measured values were in the range $L_{Rn} = 0.25 - 0.55$ mm, with similar results obtained *in-vivo* ($L_{Rn} = 0.40 \pm 0.08$ mm, n = 14) and *ex-vivo* ($L_{Rn} = 0.39 \pm 0.07$ mm, n = 10).¹ To estimate the contribution of L_{Pb} , however, the source dwelling time should be several days, such that ²¹²Pb reaches secular equilibrium with ²²⁴Ra. Under such conditions, the Alpha-DaRT diffusion process affecting the overall treatment volume is a combination of two relevant length scales governing the radon and lead diffusion in tissue. On the relevant timescale of several days ($t \gg \tau_{Rn}, \tau_{Pb}$), the specific activities of ²²⁰Rn and ²¹²Pb for a point source take on the asymptotic form:

$$\lambda_{Rn} n_{Rn}^{asy}(r,t) = \lambda_{Rn} A_{Rn} \frac{e^{-r/L_{Rn}}}{r} e^{-\lambda_{Ra}t}, \tag{1}$$

$$\lambda_{Pb} n_{Pb}^{asy}(r,t) = \lambda_{Pb} \left(A_{Pb} \frac{e^{-r/L_{Rn}}}{r} + B_{Pb} \frac{e^{-r/L_{Pb}}}{r} \right) e^{-\lambda_{Ra}t},\tag{2}$$

where n_{Rn} , n_{Pb} are the number densities of ²²⁰Rn and ²¹²Pb, λ_{Ra} , λ_{Rn} , λ_{Pb} are the decay rate constants of ²²⁴Ra, ²²⁰Rn and ²¹²Pb, and A_{Rn} , A_{Pb} and B_{Pb} are constants determined by the source and tissue properties. The radial activity distributions around the source are governed by L_{Rn} and L_{Pb} , given by:

¹In the *ex-vivo* experiments, performed to measure daughter atom migration in the absence of blood and interstitial flows, sources were inserted into the tumor immediately after their removal, with the tumors kept in PBS inside an incubator at 37° C for 30 minutes.

$$L_{Rn} = \sqrt{\frac{D_{Rn}}{\lambda_{Rn} - \lambda_{Ra}}} \approx \sqrt{D_{Rn}\tau_{Rn}},\tag{3}$$

$$L_{Pb} = \sqrt{\frac{D_{Pb}}{\lambda_{Pb} + \alpha_{Pb} - \lambda_{Ra}}} \approx \sqrt{D_{Pb}\tau_{Pb}^{eff}},\tag{4}$$

where D_{Rn} and D_{Pb} are the effective diffusion coefficients of ²²⁰Rn and ²¹²Pb, $\tau_{Rn} = 1/\lambda_{Rn}$ is the mean lifetime of ²²⁰Rn, α_{Pb} is the clearance rate constant of ²¹²Pb through the blood and $\tau_{Pb}^{eff} = \frac{1}{\lambda_{Pb} + \alpha_{Pb}}$ is the effective mean lifetime of ²¹²Pb, accounting for both radioactive decay and clearance. The total asymptotic alpha dose is also governed by the exponential terms appearing in Equation 2 as previously shown³¹. For long cylindrical sources, these exponents are replaced by the modified Bessel function of the second kind $K_0(r/L)^{32}$.

Figure 1A and B show the radial specific activity distributions of ²²⁰Rn and ²¹²Pb four days after source insertion, as obtained by numerically solving the full DL equations for an infinite 0.7 mm-diameter cylindrical source (it was shown that in the source midplane, the infinite- and finite-cylinder solutions converge to < 1%). A full discussion of the solution can be found in Refs.^{32,33}. The initial source ²²⁴Ra activity per unit length was set to 3 μ Ci/cm. The ²¹²Pb leakage probability $P_{leak} = \alpha_{Pb}/(\lambda_{Pb} + \alpha_{Pb})$ (i.e., the probability that a 212 Pb atom released from the source decays outside of the tumor) was set to 0.5, as a moderate case of blood clearance. The respective desorption probabilities of ²²⁰Rn and 212 Pb (i.e. the probability that a decay of 224 Ra on the source leads to their release into the tumor) were set as $P_{des}(Rn) = 0.45$ and $P_{des}^{eff}(Pb) = 0.55$, which are typical properties of the sources provided by the manufacturer, Alpha Tau Medical Ltd. The ²¹²Bi diffusion length and clearance rate constant were set as $L_{Bi} = 0.1L_{Pb}$ and $\alpha_{Bi} = 0$, following arguments discussed in previous publications³¹. The ²²⁰Rn specific activity around the DaRT source is shown for $0.3 \leq L_{Rn} \leq 0.5$ mm, consistent with the range recently reported by Heger *et* al^{37} . A spread of about one order of magnitude in specific activity is observed at 3 mm from the source within the measured values of L_{Rn} (Figure 1A). The ²¹²Pb activity distribution is shown separately for $L_{Pb} = 0.2, 0.4, 0.6$ and 0.8 mm while varying L_{Rn} within the same range (Figure 1B). One sees a different magnitude of the activity spread as L_{Pb} becomes the dominant scaling parameter: for $L_{Pb}=0.2$ mm the effect of varying L_{Rn} covers a spread of $\gtrsim 1$ order of magnitude at distances 3–4 mm from the source, while for $L_{Pb}=0.6-0.8$ mm, the distribution of ²¹²Pb is almost completely independent of L_{Rn} .

In order to illustrate the therapeutic effect for a particular set of DL parameters, Figure 1C shows the asymptotic alpha particle dose calculated for a hexagonal lattice of 3 μ Ci/cm ²²⁴Ra Alpha-DaRT sources at 4.5 mm spacing with $L_{Rn} = 0.4$ mm and $L_{Pb} = 0.2$ mm (other model parameters are as described above). The dose is calculated by accounting for contributions from all alpha decays in the radioactive chain. A therapeutic nominal alpha dose above 20 Gy³⁰ is administered to the tumor up to 2 mm away from the outermost sources. Beyond ~3 mm away from the lattice, lower dose levels (<1 Gy) are beneficial for sparing healthy tissue.



Figure 1: Specific activities of ²²⁰Rn (A) and ²¹²Pb (B) for $0.3 \leq L_{Rn} \leq 0.5$ mm, and in panel B, $L_{Pb} = 0.2, 0.4, 0.6, 0.8$ mm. (C) Asymptotic alpha dose in a hexagonal lattice with 4.5 mm spacing for $L_{Rn} = 0.4$ mm and $L_{Pb} = 0.2$ mm. The source ²²⁴Ra activity in (A)-(C) is 3 μ Ci/cm, with $P_{des}(Rn) = 0.45$, $P_{des}^{eff}(Pb) = 0.55$ and $P_{leak}(Pb) = 0.5$. (D) Estimated L_{eff} and (E) the relative difference with respect to the dominant diffusion length vs. the simulated L_{Pb} for $L_{Rn}=0.3, 0.4$ and 0.5 mm. (F) Illustration of the infinitesimal contribution to the integral in the line source approximation in Equation 6.

2.2 Effective diffusion length

After 4–5 days of Alpha-DaRT treatment, the spread of activity inside the tumor is governed by both L_{Rn} and L_{Pb} , as shown in Equation 2 and illustrated in Figure 1B. However, when considering the radial distribution of activity around the source, the determining factor is the dominant diffusion length (either L_{Rn} or L_{Pb}). In practice, this is embodied by the use of an effective diffusion length, L_{eff} , which can correspond to either the dominant diffusion length (if there is one) or be comprised of contributions from both if they are of comparable value. Note that L_{eff} is always the larger of the two diffusion lengths if the spatial profile is fitted at a sufficiently large distance from the source; deviations from this rule are observed if the fit is done at short distances, which is sometimes dictated by the size of the tumor or the quality of the tissue section. In addition, if diffusion is the main, but not only, process occurring inside the tumor, L_{eff} can also be affected by the contribution of other processes that are not currently included in the DL model (e.g. anisotropic vascular convective effects). To avoid potential bias by such effects, which generally appear farther away from the source and tend to increase L_{eff} , the fit region is conservatively limited to small radial distances from the source (0.5–2 mm). Under this approximation, the asymptotic distribution of 212 Pb activity for a point source is given by:

$$\lambda_{Pb} n_{Pb}^{asy}(r,t) \approx \lambda_{Pb} C_{Pb} \frac{e^{-r/L_{eff}}}{r} e^{-\lambda_{Ra}t},$$
(5)

where the spatial activity profile is determined by one parameter L_{eff} . This parameter can now be estimated by measuring the spatial distribution of ²¹²Pb or moreover, the ²¹²Bi progeny that appears to be in local secular equilibrium³¹. This allows us to utilize the autoradiography approach based on recording the alpha particles emitted by ²¹²Bi and ²¹²Po.

The accuracy of the one-parameter L_{eff} approach was assessed by simulation within the DL framework in the following manner. A full numerical calculation was performed for an infinite cylindrical source, varying the diffusion lengths over the ranges $0.3 \leq L_{Rn} \leq 0.5$ mm and $0.2 \leq L_{Pb} \leq 1.0$ mm, with the other model parameters as above. As done in Ref.³⁷, to obtain L_{eff} from the simulated data, an approximate analytical expression was used for fitting the solution of the DL equations, with the source considered as a finite line source consisting of point-like segments (this is justified since the slope of the logarithmic fall-off of the activity does not depend on the source diameter³²). The specific activity of ²¹²Bi in the source midplane was extracted in the simulation at t = 4 days and fitted assuming the line-source model:

$$\lambda_{Bi} n_{Bi}^{asy}(r) = A \int_{-l/2}^{l/2} \frac{e^{-\sqrt{r^2 + z^2}/L_{eff}}}{\sqrt{r^2 + z^2}} dz, \tag{6}$$

where the integral is along the source's 6.5 mm length (as used in *in vivo* experiments), summing contributions from point-like elements dz, with and A and L_{eff} as free parameters (see Figure 1F). Four different fit regions were defined starting from 0.5 mm and ending with r=1 mm, r=1.5 mm, r=2 mm and r=2.5 mm. Figure 1D shows the fitted L_{eff} for the

region r = [0.5, 2] mm as a function of L_{Pb} for $L_{Rn} = 0.3, 0.4$ and 0.5 mm, with Figure 1E showing the relative deviation of L_{eff} from the dominant simulated diffusion length. For $L_{Rn} = 0.4$ mm and $L_{Pb} \gtrsim 0.4$ mm, the fitted L_{eff} can overestimate the dominant diffusion length by up to ~ 30%. For cases where ²¹²Pb diffusion is sub-dominant ($L_{Pb} < L_{Rn}$), L_{eff} can overestimate L_{Rn} on the level of ~ 10 - 20%. For $L_{Pb} \approx 0.2$ mm, L_{eff} is consistent with L_{Rn} to a few %.

2.3 Experimental Materials and Procedures

The details of the methodology and materials for growing cell cultures and tumor inoculation are given in Appendix A. The cell lines used were: SQ2 (murine) for SCC (including a reanalysis of data obtained in previous studies at Tel Aviv University (TAU)), MDA-MB-231 (human) and 4T1 (murine) for triple-negative breast cancer (TNBC), PANC1 (human) and PANC2 (murine) for pancreatic duct adenocarcinoma (PDAC), MC38 (murine) and HCT116 (human) for colon carcinoma, and PC3, C4-2 and LNCaP (all human) for prostate carcinoma. All tumors were grown subcutaneously (except for five orthotopic 4T1 tumors) and treated with a single Alpha-DaRT source, inserted by a uniquely designed preclinical applicator. Tumors were grown across a range of sizes in order to inspect the dependence of the diffusion parameters on the tumor mass, under the expectation that larger tumors are characterized by a larger necrotic volume. In all recent experiments, the sources—made of 316LVM stainless steel—were loaded with 3 μ Ci ²²⁴Ra, and were 0.7 mm in diameter and 6.5 mm in length ³⁸. In the previous studies at TAU, the sources carried $0.5 - 3.3 \ \mu \text{Ci}^{224} \text{Ra}$, and were 0.3 mm in diameter and 5 mm long. The manufacturer guarantees that source activity and desorption probability are within 10% of their nominal values. In a subgroup of these experiments (referred to as "TAU point source") the activity was limited to $\sim 1 \text{ mm}$ from the source tip.

The autoradiography measurement procedure was similar to the one described in a previous publication¹². Histological sections (10- μ m thick), cut approximately perpendicular to the source axis and laid on glass slides were placed on a 20 × 40 cm² tritium-sensitive phosphorimaging plate (BAS-IP TR2040S, Fujifilm, Japan) over a 12 μ m Mylar foil to prevent direct contact with the plate, and left for a one-hour-long exposure. The plate was then scanned by an image reader (FLA-9000, Fujifilm, Japan) obtaining a gray-level (GL) output image with 100 μ m pixels. For the additional SQ2 dataset, the scanner used was FLA-2000. The conversion from GL to photo-stimulated luminescence (PSL) and then into activity is described in Appendix A.2. As noted above, since ²¹²Pb ($t_{1/2} = 10.62$ h) is a beta emitter, and ²²⁰Rn will have completely decayed by the time the slides are placed on the phosphor plate ($t_{1/2} = 55.6 s$), what is being imaged during the exposure are in fact the alpha decays of ²¹²Bi ($t_{1/2} = 60.55$ min) and ²¹²Po ($t_{1/2} = 0.30 \ \mu$ s), which occur essentially at the same place where ²¹²Pb decays.

On average 5–7 glass slides were processed from the center of each tumor. Each slide had 1-3 consecutive histological slices. A section was excluded from the analysis in case of severe tissue damage giving rise to a distorted activity distribution. An additional requirement was that the total PSL count of the section is >800 (estimated as the noise level from

the tail of the total PSL distribution across different tumors). Finally, tumors that had at least two histological sections passing all the requirements were considered for the final selection. To account for possible machine-dependent differences in image production, raw PSL images recorded by the FLA-9000 phosphor-imaging system were cross-calibrated with the iQID camera³⁹ using the exact same tumor sections. The latter device does not require image deconvolution due to the event-by-event imaging of alpha decays (with an accuracy of ~ 20 μ m for each alpha-particle hit), and therefore allows for direct L_{eff} estimation from the recorded image. However, due to the longer exposure times (12–24 h) and limited active area (5-cm diameter) of the iQID system employed here, its throughput is much lower compared to the 40 × 20 cm² phosphor imaging plate. A detailed explanation of the cross-calibration can be found in Appendix A.2. An overall correction factor of 1.09 ± 0.11 was applied per tumor to L_{eff} measured from phosphor imaging.

2.4 Estimating L_{eff} from data

To estimate L_{eff} from the spatial PSL distribution in the tumor section, the source position was determined either manually when the source left a recognizable central opening ("hole") in the tumor tissue, or by calculating the center of gravity of all pixels in the "hottest" region of the image weighted by their PSL level. The measured specific activity profile, averaged over concentric rings centered on the estimated source position, was fitted by the model with L_{eff} as a free parameter according to the procedure explained in Section 2.1 and using Equation 6, by employing the 'lsqnonlin' Matlab function with a linear-log regression model (that uses the Levenberg-Marquardt algorithm⁴⁰). A comparison between the two methods for estimating the source position on a few representative cases showed that their respective estimates for L_{eff} are consistent to within $\leq 10\%$.

Four examples of histological sections and the corresponding L_{eff} fits are given in Figure 2. For each tumor, the left panel shows the PSL distribution across the section, and the right panel shows the ring-averaged ²¹²Bi specific activity as a function of the radial distance from the estimated source position. The model (blue) is fitted to the data (red) in the region 0.5–2 (or 2.5) mm as described above. The fit region is selected based on the data distribution to include the exponential fall-off of activity, typically over two orders of magnitude. The radial fit region falls in most cases within 2 mm from the source position. The fit model was always applied in the source midplane (no z offset) as variation of ±2 mm showed no significant impact on the fitted L_{eff} (as discussed also in Ref.³²). Finally, $\langle L_{eff} \rangle$ per tumor was calculated as an average over the histological sections used in the analysis with the uncertainty defined as one standard deviation across the sections.

2.5 $P_{leak}(Pb)$ measurements

To determine $P_{leak}(Pb)$, both the total ²¹²Pb activity in excised tumors Γ_{Pb}^{tum} and the ²²⁴Ra activity of the extracted source Γ_{Ra}^{src} were measured, using a well-type NaI(Tl) detector (Hidex Automatic Gamma Counter). The measurement focused on a region surrounding the 239keV gamma line of ²¹²Pb (intensity 43.6%), considering (for the source) the contribution of the 241-keV gamma of ²²⁴Ra (intensity 4.1%). The activities were corrected to the time of tumor removal, t_R . The effective desorption probability $P_{des}^{eff}(Pb)$ was measured for a few selected cases, following a procedure described in Ref³¹, and found to be 0.53 ± 0.02 . The measured source activity was within 8% of the value reported by the manufacturer. The leakage probability was calculated for each tumor as follows, assuming a global value $P_{des}^{eff}(Pb) = 0.53$.

For $t \gg \tau_{Rn}$ the total number of ²¹²Pb atoms inside the tumor $N_{Pb}^{tum}(t)$ follows ³¹:

$$\frac{dN_{Pb}^{tum}}{dt} = P_{des}^{eff}(Pb)\Gamma_{Ra}^{src}(t) - (\lambda_{Pb} + \alpha_{Pb})N_{Pb}^{tum}.$$
(7)

The source activity is described as:

$$\Gamma_{Ra}^{src}(t) = \Gamma_{Ra}^{src}(0)e^{-\lambda_{Ra}t} \tag{8}$$

and hence the ²¹²Pb activity in the tumor as a function of time is given by:

$$\Gamma_{Pb}^{tum}(t) = \lambda_{Pb} N_{Pb}^{tum}(t) = \frac{\lambda_{Pb}}{\lambda_{Pb} + \alpha_{Pb} - \lambda_{Ra}} P_{des}^{eff}(Pb) \Gamma_{Ra}^{src}(0) \left(e^{-\lambda_{Ra}t} - e^{-(\lambda_{Pb} + \alpha_{Pb})t} \right).$$
(9)

For a time of tumor removal (t_R) much longer than the ²¹²Pb half-life $(t_R \gg \tau_{Pb})$:

$$\Gamma_{Pb}^{tum}(t_R) = \frac{\lambda_{Pb}}{\lambda_{Pb} + \alpha_{Pb} - \lambda_{Ra}} P_{des}^{eff}(Pb) \Gamma_{Ra}^{src}(t_R).$$
(10)

Given $P_{des}^{eff}(Pb)$, by measuring $\Gamma_{Pb}^{tum}(t_R)$ and $\Gamma_{Ra}^{src}(t_R)$, α_{Pb} can be derived from Equation 10, and consequently from it the ²¹²Pb leakage probability as:

$$P_{leak}(Pb) = \frac{\alpha_{Pb}}{\lambda_{Pb} + \alpha_{Pb}}.$$
(11)

Now from Equation 4, and $\tau_{Pb}^{eff} = \frac{1}{\lambda_{Pb} + \alpha_{Pb}}$, it follows:

$$\frac{1}{\lambda_{Pb} + \alpha_{Pb}} = \frac{L_{Pb}^2}{D},$$

and from Equation 11:

$$P_{leak}(Pb) = 1 - \frac{\lambda_{Pb}}{\lambda_{Pb} + \alpha_{Pb}} = 1 - \frac{\lambda_{Pb}L_{Pb}^2}{D_{Pb}}.$$
(12)

In case L_{Pb} is the dominant diffusion length $(L_{eff} \approx L_{Pb})$, this relation should also hold for L_{eff} . Therefore, an anti-correlation between $P_{leak}(Pb)$ and L_{eff} can indicate a lead-dominated diffusion scenario. Conversely, if $P_{leak}(Pb)$ is independent of L_{eff} , one may conclude that the diffusion is radon-dominated, with $L_{Rn} > L_{Pb}$.



Figure 2: Examples of PSL images from histological sections (left) and the corresponding radial L_{eff} fits (right). Histological types and cell lines are: TNBC 4T1 0.62 g tumor (A,B), PDAC PANC1 0.68 g tumor (C,D), prostate C4-2 0.95 g tumor (E,F), colon HCT116 0.58 g tumor (G,H).

3 Results

3.1 Effective diffusion length in tumors

The effective diffusion parameter L_{eff} was measured for 113 tumors in total and found to be in the range of 0.2–0.7 mm across different tumor types and sizes, indicating a broad range for different tumors. Only data for prostate cancer cell lines showed a significant increase in L_{eff} with tumor mass (*p*-value < 0.05). The measurements of radon diffusion length, L_{Rn} , for corresponding cell lines³⁷ are consistent with the L_{eff} measurements when performing a one-sided ANOVA test for each histological type (at 0.05 significance).

Figure 3A shows L_{eff} for SQ2 tumors as a function of tumor mass (0.2–2 g) for the three protocols described in Section 2.3: the main protocol ("BGU data") and the two variations: line sources with varying activities ("TAU data") and point source measurements ("TAU point source"). L_{eff} values are from 0.3 to 0.7 mm and show no dependence on tumor mass (linear coefficient 0.03 ± 0.21 at 95% CI). The error bars indicate the total uncertainty after combining the statistical uncertainty arising from averaging over histological sections and systematic uncertainty from the iQID calibration correction. The average measured value over all SQ2 tumors is $\langle L_{eff} \rangle = 0.42 \pm 0.09$ mm. The results for the diffusion length associated with ²²⁰Rn from Ref.³⁷ are added for comparison. One-sided ANOVA indicated no difference between different L_{eff} samples or L_{eff} and the published L_{Rn} data. The L_{eff} (for "BGU data") and L_{Rn} measurements are also consistent when performing the Mann-Whitney U-test (*p*-value = 0.7).

Figure 3B shows the results for TNBC for 0.15–0.97 g tumors: 4T1 subcutaneous, 4T1 orthotopic and MDA-MB-231. L_{eff} values range from 0.3–0.6 mm with no apparent mass dependence (linear coefficient 0.06±0.14 at 95% CI). Results for orthotopic and subcutaneous 4T1 tumor models are consistent in the measured data (*p*-value = 0.3 for Welch's t-test) and no difference to the human model is observed (*p*-value = 0.2 for the same statistic). The average value for 4T1 tumors is $\langle L_{eff} \rangle = 0.41 \pm 0.09$ mm and for MDA-MB-231, $\langle L_{eff} \rangle = 0.38 \pm 0.05$ mm. The measured values for the ²²⁰Rn diffusion length (open red circles) are in agreement with the rest of the data points (*p*-value = 0.3 for one-sided ANOVA).

Results for PDAC tumors are shown in Figure 3C for PANC1 and PANC2 models. L_{eff} ranges from 0.23 mm to 0.50 mm, while low values about 0.2 mm are measured even for PANC2 tumors of ~2 g. The average value measured for PANC1 tumors is $\langle L_{eff} \rangle = 0.33 \pm 0.08$ mm and for PANC2 tumors $\langle L_{eff} \rangle = 0.30 \pm 0.07$ mm, which are the lowest measured values compared to other histologies. The $L_{\rm Rn}$ values (open red circles) are consistent with the rest of the measurements (*p*-value = 0.1 for one-sided ANOVA for the three groups).

Data for prostate cancer cell lines—PC3, C4-2 and LNCaP—are shown in Figure 3D. The tumors are in the 0.1–3 g mass range and L_{eff} values are between 0.2–0.7 mm with a significant increase with tumor mass (linear coefficient yields 0.11 ± 0.06 mm/g at 95% CI). The average values are 0.36 ± 0.11 mm, 0.40 ± 0.13 mm and 0.52 ± 0.13 mm for LNCaP, PC3 and C4-2, respectively. Only one data point for ²²⁰Rn measurement is reported and is consistent with the L_{eff} values shown. One-sided ANOVA indicates that the samples are

Histological type	Cell line	$\langle L_{\rm eff} \rangle \pm ({\rm stat}) \pm ({\rm syst}) \ ({\rm mm})$
SCC	SQ2	$0.42 \pm 0.09 \pm 0.04$
TNBC	MDA-MB-231	$0.38 \pm 0.03 \pm 0.03$
	4T1	$0.42 \pm 0.09 \pm 0.04$
	4T1 orthotopic	$0.46 \pm 0.08 \pm 0.04$
PDAC	PANC1	$0.33 \pm 0.08 \pm 0.03$
	PANC2	$0.30 \pm 0.06 \pm 0.03$
Prostate cancer	PC3	$0.40 \pm 0.13 \pm 0.04$
	C4-2	$0.52 \pm 0.13 \pm 0.05$
	LNCaP	$0.36 \pm 0.10 \pm 0.03$
Colon cancer	HCT116	$0.45 \pm 0.13 \pm 0.04$
	MC38	$0.34 \pm 0.05 \pm 0.03$

Table 1: Average $\langle L_{eff} \rangle$ across all measured tumors for each cell line model studied in the experiment. Statistical uncertainty is one SD across all tumors and the systematic uncertainty arises from the calibration correction described in Appendix A.2.

not consistent (*p*-value < 0.05) which presumably arises from LNCaP tumors measured at small masses (below 1 g) and C4-2 and PC3 sampled until 3 g. C4-2 tumors yield higher values when compared with PC3 and LNCaP (*p*-values 0.07 and 0.02, respectively).

Figure 3E shows the measured L_{eff} for colon cancer tumors up to 2 g. Human HCT116 model shows systematically larger L_{eff} values compared to its mouse counterpart MC38 (*p*-value = 0.02 for Welch's t-test). No significant increase with the tumor mass is observed for both data sets when fitted with linear regression. The average values across all tumors are $\langle L_{eff} \rangle = 0.45 \pm 0.13$ mm for HCT116 and $\langle L_{eff} \rangle = 0.34 \pm 0.06$ mm for MC38. One MC38 tumor is shown for $L_{\rm Rn}$ measurement (red open circles) and is consistent with other points. The full summary of average values for measured $\langle L_{eff} \rangle$ for each histological type is given in Table 1. The quoted uncertainties are separated in statistical contributions arising from the variations between different tumors and a systematic contribution from the calibration correction.

3.2 Leakage measurement

 $P_{leak}(Pb)$ was measured for 77 tumors originating from 10 cell lines (part of the dataset used for L_{eff}) and found to span a wide range from 0.1 to 0.9, with varying dependence on tumor mass. Figure 4 shows $P_{leak}(Pb)$ vs. tumor mass for different cell lines. In panel A, similarly measured SQ2 data (26 tumors) from Ref.¹² show a significant decrease in $P_{leak}(Pb)$ with tumor mass. TNBC data in panel B suggest that for subcutaneous 4T1 tumors $P_{leak}(Pb)$ is mass-independent, while for orthotopic 4T1 and MDA-MB-231 $P_{leak}(Pb)$ generally decreases with tumor mass. Only 3 data points were measured for pancreatic tumors in the range from 0.5 to 0.8. For prostate cancer, PC3 tumors show no mass dependence with $P_{leak}(Pb) \sim 0.5$ on average, while C4-2 and LNCaP tumors display an apparent decrease of leakage with mass below ~ 0.5 g. Lastly, for colon cancer tumors (D) there is no observed dependence of leakage on tumor mass, with $P_{leak}(Pb) \sim 0.5$. Correlations between the measured $P_{leak}(Pb)$ and $\langle L_{eff} \rangle$ per tumor were inspected for each cell line. Equation 12, which holds for L_{eff} instead of L_{Pb} if the diffusion is ²¹²Pb-dominated in secular equilibrium, predicts a negative correlation between the variables. However, a statistically significant negative correlation was observed only in MC38 and C4-2 tumors when inspected with two-dimensional linear regression and Pearson's correlation coefficient, as described in Appendix A.3.



Figure 3: Fitted $\langle L_{eff} \rangle$ per tumor as a function of the tumor mass for different histological types and corresponding cell lines: SCC (A), TNBC (B), PDAC (C), prostate cancer (D) and colon cancer (E). SCC results contain additional data sets for comparison (see text for details). Dashed lines represent linear fits and the error bars show the total uncertainty for each tumor measurement.



Figure 4: Measured $P_{leak}(Pb)$ per tumor as a function of the tumor mass for different histological types and corresponding cell lines: SCC (A), TNBC (B), prostate cancer (C) and colon cancer cell lines (D). SCC results from Ref.¹² are added to panel A for completion.

4 Implication for the dose around a single source

The observed root-mean-square spread in the measured values of L_{eff} for a given tumor type ranges from 8% to 33%, with the largest variations recorded for prostate PC3 tumors. This spread can result (at least partially) from local variations in necrotic domains (which are more prevalent in larger tumors) and vascular density, which is typically higher in the periphery of the tumor. Since the Alpha-DaRT source in these experiments is not much shorter than the tumor size, different sections along the source axis can present strong variations in L_{eff} . Incorporating such variations into a realistic dosimetry model is far from trivial and requires knowledge of the size distribution of tissue domains with different diffusion and leakage characteristics. As a first step towards estimating the effect of the observed variations, we adopt a simple and pragmatic approach in which the tissue around the source is uniform (such that the simple DL model equations hold with constant coefficients) but the values of the diffusion lengths and leakage probability take a range of values consistent with the observed spread.

Figure 5 shows how the observed variations in L_{eff} and $P_{leak}(Pb)$ affect the calculated dose profile in the midplane of the source under this simplistic scenario (all sources are assumed to be 0.7 mm in diameter, with 3 μ Ci/cm ²²⁴Ra, $P_{des}(Rn) = 0.45$, and $P_{des}^{eff}(Pb) =$ 0.55). The calculation was done assuming that L_{eff} represents L_{Rn} , with a spread of values corresponding to \pm one standard deviation. The diffusion is assumed to be radon-dominated, with $L_{Pb} = 0.1 - 0.3$ mm and $P_{leak}(Pb) = 0.2 - 0.8$. (The nominal values are taken as $L_{Pb} = 0.2 \text{ mm}$ and $P_{leak}(Pb) = 0.5$.) Each panel shows a band corresponding to the radial profile of the alpha dose (in color) and low-LET dose in grey. The latter was calculated by approximating the source to a line, and assuming that all electron and photon emissions originate from the source (i.e., using the "line-source/no-diffusion" approximation discussed in our previous publication⁴¹, and shown to be accurate to $\sim 10 - 15\%$ when compared to a full-diffusion simulation). Since we neglect diffusion when calculating the low-LET dose, the low-LET dose profile is the same for all tumor types. Variations in the model parameters lead to variations in the radial distance at which the asymptotic alpha dose reaches a certain reference value (e.g., 10 Gy). For SCC tumors, the 10-Gy alpha dose level is reached at $r = 2.6 \pm 0.4$ mm, for TNBC at $r = 2.4 \pm 0.3$ mm, for PDAC at $r = 2.2 \pm 0.4$ mm, for prostate tumors at $r = 2.6 \pm 0.4$ mm, and for colon tumors at $r = 2.7 \pm 0.3$ mm. Variations across tumor types are thus fairly small. A 1-cm-long Alpha-DaRT source carrying 3 μ Ci 224 Ra per cm length creates a cylindrical region with a nominal diameter of 4.4 - 5.4 mm in which the asymptotic alpha dose is higher than 10 Gy.



Figure 5: Alpha and low-LET radial dose profiles for the studied tumor types, based on the observed variations in L_{eff} and $P_{leak}(Pb)$: SCC (A), TNBC (B), PDAC (C), prostate (D) and colon (E). Diffusion is assumed to be radon-dominated with L_{eff} representing L_{Rn} . The source, in all cases, carries 3 μ Ci/cm ²²⁴Ra and is 0.7 mm in diameter. The desorption probabilities are $P_{des}(Rn) = 0.45$ and $P_{des}^{eff}(Pb) = 0.55$. The low-LET dose is calculated by approximating the source to a line and assuming that all electron and photon emissions originate from it with no diffusion. Lines are for the nominal values of L_{Rn} , L_{Pb} and $P_{leak}(Pb)$, with the bands corresponding to variations of all parameters within the ranges shown in the legends.

5 Discussion

In this study, we report on *in vivo* measurements of the effective diffusion length L_{eff} and the ²¹²Pb leakage probability $P_{leak}(Pb)$. L_{eff} was measured in 113 mice across 10 cell lines and was found to lie in the range 0.2–0.7 mm for tumor masses between 0.1 and 3 g. Measured $P_{leak}(Pb)$ values in a total of 77 tumors are between 10–90% with a smaller spread for larger tumors around ~ 50%. While these data are taken from mice-borne tumors (of both murine and human origin), this is at present the only way to estimate the DL model parameters towards treatment planning in clinical trials, since no external imaging or internal dose measurements techniques can provide the spatial resolution required to extract the sub-mm effective diffusion length.

The consistency between most measured values for L_{eff} and the previously published results for L_{Rn} suggests that in those cases, the diffusion is radon-dominated rather than leaddominated, or that the two diffusion lengths are of similar magnitude. Based solely on the DL model, for the measured range of L_{eff} (0.2–0.7 mm) and the previously reported L_{Rn} values between 0.3–0.5 mm, the estimated L_{Pb} could lie in the 0.2–0.5 mm range (for the fit region of 0.5–2 mm from the source). It is important to note that in the lead-dominated diffusion case, one would expect to find a negative correlation between the measured $P_{leak}(Pb)$ and L_{eff} . Since such correlations are apparently observed in some measured cell lines (MC38 and C4-2 tumors), some contribution of ²¹²Pb diffusion cannot be excluded. An increase in L_{eff} as a function of tumor mass observed in some cell lines may be understood by additional effects of tissue necrosis and considerable ²¹²Pb contribution. A plausible explanation for the observed decrease in ²¹²Pb leakage with tumor mass is that for large tumors, a source placed roughly in the tumor center lies farther away from vascular-rich regions in the tumor periphery, and hence the average clearance time of ²¹²Pb is longer. The role of vasculature could further be investigated using histopathology and imaging techniques.

To probe in more detail the interplay between the diffusion lengths, more *in vivo* measurements are required: experiments expanding the histology and tumor mass coverage of L_{Rn} measurements as well as tackling the vascular contribution further away from the source. More orthotopic models are being envisioned, such as for colon and brain cancer.

Based on the presented results of parameter measurements, it appears that a choice of 4-mm spacing (preferably in a hexagonal source configuration) offers a reasonable starting point for ongoing and future clinical trials. For SCC, treatments employing sources carrying 2 μ Ci/cm ²²⁴Ra placed at a nominal spacing of 5 mm resulted in a complete response (CR) rate of 78.6%. Reducing the nominal spacing to 4 mm and increasing the ²²⁴Ra activity to 3 μ Ci/cm further improved the CR rate to ~ 90%, with a two-year local recurrence-free survival of 77%. Similar results may be expected in other tumor types, especially if their corresponding EBRT prescription dose is not much higher than that of SCC and if they are easily accessible from the outside (e.g., breast cancer). However, treating hard-to-reach tumors such as in the pancreas or colon metastases in the lungs or liver, may require increased source activities to compensate for the difficulty in precise source placement. A similar increase in activity may also be needed for prostate tumors, where—although hexagonal

source placement is feasible—the perscription dose may be much higher.

6 Conclusion

This study presented results from preclinical *in vivo* experiments with Alpha-DaRT for the purpose of providing a reasonably informed starting point for treatment planning in ongoing and future clinical trials on various tumor types. The measurements indicate that the diffusion spread around the Alpha-DaRT source is radon-dominated. With the estimated values of DL model parameters extracted from these studies, a feasible treatment plan can be established that provides therapeutic dose coverage across the hexagonal Alpha-DaRT source lattice. Such plans should consider the effect of tumor-specific parameters and the required biological effective dose when setting source spacing and activities. The presented data is a valuable guide for initial planning in Alpha-DaRT clinical protocols with an increasingly growing number of studies being planned for the near future.

Appendix A Detailed description of materials and methods

A.1 Cell culture and tumor inoculation

Cell culture Cells were grown in 5% CO_2 in a humidified incubator at 37° C. All media were supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 μ g/ml) (all obtained from Gibco, Thermo Fisher Scientific, MA, USA). The SQ2 (squamous cell carcinoma, SCC), MDA-MB-231 and 4T1 (both triple negative breast cancer, TNBC), PANC2 (pancreatic duct adenocarcinoma, PDAC), and MC38 (colon carcinoma) cell lines were provided by Prof. Yona Keisari (Sackler School of Medicine, Tel-Aviv University, Israel). In total, 9 SQ2 tumors, 16 4T1, 5 MDA-MB-231, 8 PANC2 and 10 MC38 tumors were grown for this study. The three prostate carcinoma cell lines - PC3 (9) tumors), C4-2 (8 tumors) and LNCaP (9 tumors) - were provided by Dr. Benesova Martina (DKFZ-Heidelberg, German Cancer Research Center Foundation, Heidelberg, Germany). The PANC1, PDAC cell line, was provided by Prof. Moshe Oren (Moross Integrated Cancer Center, Weizmann Institute of Science, Rehovot, Israel; 11 tumors). The colon carcinoma cell line HCT116 (in total 12 tumors) was provided by Prof. Bert Vogelstein (Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, MD, USA). All cells were grown in Dulbecco's Modified Eagle Medium (DMEM), except for 4T1 and the three prostate carcinoma cell lines, which were grown in Roswell Park Memorial Institute Medium (RPMI), and HCT116 cells, which were grown in McCoy's 5A Medium. The number of instilled cells varied from $5 \cdot 10^5$ in the case of 4T1 and SQ2 tumors to $5 \cdot 10^6$ in the case of PANC1 and the prostate carcinoma cells. In addition to these samples, autoradiography data from a previous measurement campaign (denoted as "TAU data"), including 17 SQ2 tumors, were added for comparison.

Tumor inoculation The study was approved by the Ben-Gurion University Institutional Animal Care and Use Committee, and was conducted according to the Israeli Animal Welfare Act following the guidelines of the Guide for Care and Use of Laboratory Animals (National Research Council, 1996) [permit no. IL-78-12-2018(E) and IL-44-08-2021 (E)]. BALB/c mice (6-12 weeks old) were obtained from Envigo (Jerusalem, Israel). NOD scid gamma (NSG) mice (6-12 weeks old) were obtained from the breeding colony of Ben-Gurion University, Beer-Sheva, Israel. C57BL/6 mice were bred 'in-house' at the animal facility of Ben-Gurion University. Mice were inoculated subcutaneously with cells in 100-200 μ l Dulbecco's phosphate-buffered saline (DPBS) (Gibco, 14190144, Thermo Fisher Scientific, MA, USA) into the low lateral side of the back. Depending on the target tumor mass, the inoculation-to-treatment time varied between 8-99 days. Figure 6 shows the experimental sequence starting with tumor inoculation in (i).

Alpha-DaRT source insertion Alpha-DaRT sources made out of 316LVM stainless steel loaded with 3 μ Ci ²²⁴Ra (0.7 mm in diameter and 6.5 mm long), were placed near the tip



Figure 6: Experimental sequence: (i) tumor inoculation – cells were injected subcutaneously in 0.1-0.2 ml PBS; after a period of 8-50 days of tumor development (depending on the cell line growth kinetics) (ii) the tumors were treated with a single Alpha-DaRT source insertion into the middle of the tumor while mice were anesthetized. Four to five days later (iii) the tumors were removed and cut in the middle, and the source was extracted and placed in 1.5 ml tube full of water. The tumors were weighed, placed in 20 ml scintillation bottles on dry ice and taken to the Hidex gamma counter for activity measurement (iv). Following source removal, both halves of the tumor were subjected to histological frozen-sectioning by LEICA CM 1520 cryostat (v). The 10 μ m-thick sections were then placed on positively charged glass slides, with 250-300 μ m intervals between each section, creating a series of sequential sections (typically, between 5 to 15 slides per tumor). Finally, after fixation, slides were taken to the autoradiography system, Fujifilm FLA-9000 (vi).

of an 18-gauge needle attached to a 2.5 ml syringe (Picindolor, Rome, Italy) and inserted into the tumor by a plunger placed internally along the syringe axis (Figure 6 (ii)). Source insertion was done under anesthesia with isoflurane. Source location was verified using a Geiger counter (RAM GENE-1, Rotem industries, Israel) after insertion.

Frozen section preparation Four to five days post Alpha-DaRT treatment, the tumors were excised (as a whole). Each tumor was cut to two halves, in the estimated location of the source center, perpendicular to the source's insertion axis as shown in Figure 6 (iii). The source was then pulled out using surgical tweezers and was placed in a 1.5 ml microcentrifuge tube filled with 1 ml of water. The tumor was placed for 1 hour in dry ice at -80°C and then moved to a 20 ml scintillation bottle on dry-ice and taken for total ²¹²Pb activity measurement in a Hidex Automatic Gamma Counter (Figure 6 (iv)).

Following the activity measurement, both halves of the tumor were subjected to histological frozen sectioning by a LEICA CM 1520 cryostat (Buffalo Grove, IL, USA), Figure 6 (v). The 10- μ m-thick sections were then placed on positively charged glass slides, with 250-300 μ m intervals between each section, creating a series of sequential samples (between 5 to 15 per tumor). Following the sectioning, slides were fixed with 4% paraformaldehyde (sc-281692, Santa Cruz Biotechnology Inc., Dallas, Texas, USA) for 10 minutes and rinsed twice with PBS for 10 minutes each time. Immediately after the fixation step, slides were taken to the autoradiography system (Figure 6 (vi)).

A.2 Phosphor imaging calibration

The conversion from gray-level (GL) to photo-stimulated luminescence (PSL) level is given by the image reader and is of the form $I_{PSL} = \exp(a I_{GL} + b)$, where a, b depend on the specific scanner resolution and I is the image matrix. The recorded PSL level intensity patterns were converted to activity using ²¹²Pb calibration samples measured separately. The samples were prepared by the following procedure. A small cylindrical plastic container (28.5 mm diameter and 3 mm height) is placed inside a low-pressure chamber (<0.1 mbar) with a ²²⁸Th source at the bottom of the container and an aluminium sheet glued to its top. Over several days, ²²⁴Ra ions recoiling from the ²²⁸Th source are implanted in the aluminium sheet. Then, the ²²⁴Ra implanted container top is removed and placed on top of a second container, holding a plastic sheet at the bottom, which is covered by an adhesive tape with a circular 5 mm-diameter hole in the middle. In this configuration, the recoiling daughters of ²²⁴Ra are allowed to hit the exposed circular part of the plastic sheet over a prescribed duration (typically several hours), creating a circular patch of ²¹²Pb with a typical activity in the range 5-200 Bq. Once this stage is finished, the adhesive tape is removed, leaving only the circular exposed plastic as the active calibration sample, which is then taken to the Hidex gamma counter to determine its ²¹²Pb activity. Finally, the source, with its back side glued to a glass slide, is taken to the Fuji system to be measured along with the tumor sections. A total of four calibration measurements were carried out, yielding a linear relation between PSL and ²¹²Pb activity.



Figure 7: Phosphor imager PSL-to-activity calibration curve.

To account for possible machine-dependent differences in image production, raw PSL images recorded by the phosphor-imaging system were cross-calibrated with the iQID camera³⁹ using the exact same tumor sections. The iQID operates as follows: the samples are placed face-down on a scintillating material - in this case, a sheet of ZnS:Ag (Eljen technologies, EJ-440-100). Each alpha particle impinging on the scintillating sheet releases photons. These pass through an image intensifier, and, following a series of lenses, imaged by a CCD sensor. Each flash of light is referred to as a "cluster". The cluster images are constantly sent to the PC operating the iQID, where each cluster's center is identified. The XY coordinates, as well as the timestamp of each cluster, are stored in a list file. Since this analysis occurs on an event-by-event basis, there is no convolution with each cluster's point spread function (PSF) in the final images and, thus, no need for de-convolution when analyzing the iQID images. The resulting image is then corrected for geometrical aberrations using the lensdistort() MATLAB script 42 . The correction parameter is obtained by imaging a printed grid pattern with known distances between the grid points, such as the one shown in Figure 8. After applying the correction, the average distance between dots in the image acquired with the iQID is accurate to 0.08%.

Figure 9 shows an example of one section, from a 0.49 gr, SQ2 mice-borne tumor, measured in both the phosphor imaging system (A) and the iQID system (B). Additionally, it shows the extracted activity profiles and diffusion lengths from the respective measurement system (C)-(D). As seen in this example, the L_{eff} value extracted from the raw PSL image from the phosphor imaging system is lower than the iQID value. This is true for 90% of the measured sections. The reason for this could be some sharpening of the image being applied internally by the phosphor imaging system. In total, 77 histological sections from six tumors were imaged for comparison between the systems. Averaging over all sections, the resulting ratio is: $L_{iQID}/L_{phosphor\ imager} = 1.09 \pm 0.11$. This correction factor is thus applied to all measured phosphor-imaged samples accounting for its uncertainty (i.e., the L_{eff} value extracted from the raw PSL image is multiplied by this factor).



Figure 8: (A) the grid pattern used for the distortion correction. (B) the raw image of the grid pattern acquired using the iQID system. (C) the corrected grid image.

A.3 Correlation between diffusion and leakage

The possible correlation between the measured $P_{leak}(Pb)$ and $\langle L_{eff}^2 \rangle$ was inspected for all cell lines by using a linear fit, minimizing the χ^2 calculated using uncertainties in both variables⁴³. In addition, Pearson's correlation coefficient ρ and the corrected Pearson's correlation coefficient was calculated for each cell line data. The correction to the Pearson coefficient was calculated by considering the uncorrelated additive uncertainties for $P_{leak}(Pb)$ and $\langle L_{eff} \rangle$. Statistically significant negative correlation was obtained for C4-2 ($p_1 = -3.0 \pm 0.7 \text{ mm}^{-1}$, $\rho = -0.63$, $\rho' = -0.69$ with *p*-value 0.10) and MC38 ($p_1 = -5.4 \pm 2.8 \text{ mm}^{-1}$, $\rho = -0.83$, $\rho' = -0.89$ with *p*-value 0.02). Figure 10 shows the measured correlations for all analyzed histologies with relevant fits indicated for C4-2 and MC38 data.



Figure 9: Comparison between the iQID and phosphor-imaging systems: (A) PSL image of a section measured in the phosphor imaging system. (B) cluster image of the same section measured in the iQID system. (C) PSL profiles (measured and fitted) and extracted diffusion length from the phosphor-imaging measurements. (D) the same, for the iQID measurement.



Figure 10: Calculated $P_{leak}(Pb)$ per tumor as a function of the $\langle L_{eff} \rangle$ for different histological types and corresponding cell lines: SCC (A), TNBC (B), prostate cancer (C) and colon cancer (D). Dashed lines represent the linear fit to measured points for C4-2 and MC38 cell lines together with 95% CI. The error bars represent statistical uncertainties of $\pm 1\sigma$.

References

- ¹ G. Sgouros, J. Roeske, M. McDevitt, S. Palm, B. Allen, D. Fisher, A. Brill, H. Song, R. Howell, G. Akabani, W. Bolch, R. Meredith, B. Wessels, and P. Zanzonico, MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy, Journal of Nuclear Medicine **51**, 311–328 (2010).
- ² N. K. Tafreshi, M. L. Doligalski, C. J. Tichacek, D. N. Pandya, M. M. Budzevich, G. El-Haddad, N. I. Khushalani, E. G. Moros, M. L. McLaughlin, T. J. Wadas, and D. L. Morse, Development of targeted alpha particle therapy for solid tumors, Molecules 24, 4314 (2019).
- ³ T. A. T. W. Group, Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, JAMA Oncology 4, 1765–1772 (2018).
- ⁴ M. R. McDevitt, G. Sgouros, and S. Sofou, Targeted and nontargeted α -particle therapies, Annual Review of Biomedical Engineering **20** (2010).
- ⁵ T. A. T. W. Group, Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, JAMA Oncology 4 (2018).
- ⁶ N. K. Tafreshi, M. L. Doligalski, C. J. Tichacek, D. N. Pandya, G. Budzevich, Mikalai M.and El-Haddad, N. I. Khushalani, E. G. Moros, M. L. McLaughlin, T. J. Wadas, and D. L. Morse, Development of targeted alpha particle therapy for solid tumors, Molecules **24** (2019).
- ⁷ M. Shirley and P. McCormack, Radium-223 dichloride: A review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases, Drugs **74**, 579–586 (2014).
- ⁸ Pacilio, Massimiliano et al, Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride, Eur J Nucl Med Mol Imaging. 43, 21–33 (2016).
- ⁹ Chittenden, Sarah J et al, A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases, J Nucl Med. 56, 1304–9 (2016).
- ¹⁰ Höllriegl, Vera et al, Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer, EJNMMI Physics 8, 44 (2021).
- ¹¹ M. J. Zacherl, F. J. Gildehaus, L. Mittlmeier, G. Böning, A. Gosewisch, V. Wenter, M. Unterrainer, N. Schmidt-Hegemann, C. Belka, A. Kretschmer, J. Casuscelli, C. G. Stief, M. Unterrainer, P. Bartenstein, A. Todica, and H. Ilhan, First Clinical Results

for PSMA-Targeted α -Therapy Using ²²⁵Ac-PSMA-I&T in Advanced-mCRPC Patients, The Journal of Nuclear Medicine **62**, 669–674 (2021).

- ¹² L. Arazi, T. Cooks, M. Schmidt, Y. Keisari, and I. Kelson, Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters, Phys. Med. Biol. **52**, 5025–42 (2007).
- ¹³ T. Cooks, L. Arazi, M. Schmidt, G. Marshak, I. Kelson, and Y. Keisari, Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms, International Journal of Cancer 122, 1657–1664 (2008).
- ¹⁴ L. Arazi, T. Cooks, M. Schmidt, Y. Keisari, and I. Kelson, The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis, Phys. Med. Biol. 55, 1203–18 (2010).
- ¹⁵ T. Cooks, M. Schmidt, H. Bittan, E. Lazarov, L. Arazi, I. Kelson, and Y. Keisari, Local Control of Lung Derived Tumors by Diffusing Alpha-Emitting Atoms Released From Intratumoral Wires Loaded With Radium-224, Int. J. Radiat. Oncol. Biol. Phys. 74, 966–973 (2009).
- ¹⁶ E. Lazarov, L. Arazi, M. Efrat, T. Cooks, M. Schmidt, Y. Keisari, and I. Kelson, Comparative in vitro microdosimetric study of murine- and human-derived cancer cells exposed to alpha particles, Radiation Research **177**, 280–7 (2012).
- ¹⁷ T. Cooks, M. Tal, S. Raab, M. Efrati, S. Retkopf, E. Lazarov, R. Etzyoni, M. Schmidt, L. Arazi, I. Kelson, and Y. Keisari, Intratumoral 224Ra-loaded wires spread alphaemitters inside solid human tumors in athymic mice achieving tumor control, Anticancer Res. **32**, 5315–21 (2012).
- ¹⁸ T. Cooks, L. Arazi, M. Efrati, M. Schmidt, G. Marshak, I. Kelson, and Y. Keisari, Interstitial wires releasing diffusing alpha emitters combined with chemotherapy improved local tumor control and survival in squamous cell carcinoma-bearing mice, Cancer **115**, 1791–801 (2009).
- ¹⁹ T. Cooks, L. Arazi, M. Efrati, M. Schmidt, G. Marshak, I. Kelson, and Y. Keisari, Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms, Transl Res **159**, 32–41 (2012).
- ²⁰ E. Milrot, A. Jackman, E. Flescher, P. Gonen, I. Kelson, and Y. Keisari, Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation, Invest New Drugs **31**, 333–44 (2013).
- ²¹ S. Reitkopf-Brodutch, H. Confino, M. Schmidt, T. Cooks, M. Efrat, L. Arazi, L. Rath-Wolfson, G. Marshak, I. Kelson, and Y. Keisari, Ablation of experimental colon cancer by intratumoral 224Radium-loaded wires is mediated by alpha particles released from

atoms which spread in the tumor and can be augmented by chemotherapy, Int J Radiat Biol **91**, 179–86 (2015).

- ²² Y. Keisari, I. Hochman, H. Confino, R. Korenstein, and I. Kelson, Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments, Cancer Immunol Immunother **63**, 1–9 (2014).
- ²³ H. Confino, I. Hochman, M. Efrati, M. Schmidt, V. Umansky, I. Kelson, and Y. Keisari, Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors, Cancer Immunol Immunother 64, 191–9 (2015).
- ²⁴ H. Confino, M. Schmidt, M. Efrati, I. Hochman, V. Umansky, I. Kelson, and Y. Keisari, Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alphairradiation combined with inhibitors of immunosuppression and CpG, Cancer Immunol Immunother 65, 1149–58 (2016).
- ²⁵ V. Domankevich, A. Cohen, M. Efrati, M. Schmidt, H.-G. Rammensee, S. Nair, A. Tewari, I. Kelson, and Y. Keisari, Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response, Cancer Immunol Immunother **68**, 1949–1958 (2019).
- ²⁶ V. Domankevich, M. Efrati, M. Schmidt, E. Glikson, F. Mansour, A. Shai, A. Cohen, Y. Zilberstein, E. Flaisher, R. Galalae, I. Kelson, and Y. Keisari, RIG-1-Like Receptor Activation Synergizes With Intratumoral Alpha Radiation to Induce Pancreatic Tumor Rejection, Triple-Negative Breast Metastases Clearance, and Antitumor Immune Memory in Mice, Front Oncol **10**, 990 (2020).
- ²⁷ Y. Keisari, A. Popovtzer, and I. Kelson, Effective treatment of metastatic cancer by an innovative intratumoral alpha particle-mediated radiotherapy in combination with immunotherapy: A short review, J. Phys.: Conf. Ser. **1662**, 012016 (2020).
- ²⁸ Y. Keisari and I. Kelson, The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules, Cells **10**, 228 (2021).
- ²⁹ S. Del Mare, Y. Nishri, A. Shai, M. Efrati, L. Deutsch, R. B. Den, I. Kelson, Y. Keisari, and V. Domankevich, Diffusing alpha-emitters Radiation Therapy Promotes a Proimmunogenic Tumor Microenvironment and Synergizes with PD-1 Blockade, Int. J. Radiat. Oncol. Biol. Phys. (2022).
- ³⁰ A. Popovtzer et al., Initial Safety and Tumor Control Results From a "First-in-Human" Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head and Neck, Int. J. Radiat. Oncol. Biol. Phys. **106**, 571–578 (2020).

- ³¹ L. Arazi, Diffusing alpha-emitters radiation therapy: approximate modeling of the macroscopic alpha particle dose of a point source, Phys. Med. Biol. **65**, 015015 (2020).
- ³² G. Heger, A. Roy, M. Dumancic, and L. Arazi, Alpha dose modeling in diffusing alphaemitters radiation therapy-Part I: single-seed calculations in one and two dimensions., Med Phys. 50, 1793–1811 (2023).
- ³³ G. Heger, M. Dumancic, A. Roy, and L. Arazi, Alpha dose modeling in diffusing alphaemitters radiation therapy. Part II: Lattice studies, Med Phys. **50**, 1793–1811 (2023).
- ³⁴ A. Popovtzer, A. Mizrachi, M. A. D'Andrea, N. A. VanderWalde, N. Kurman, E. Rosenfeld, R. Ben-Hur, S. R. Bellia, G. Feliciani, D. Silvern, A. Sarnelli, M. T. Ballo, P. Patra, G. N. Cohen, A. L. Damato, Y. Shkedy, R. B. Den, C. A. Barker, T. Charas, and N. Hirshoren, Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers, Cancers 16 (2024).
- ³⁵ C. S. Miller, M. Lecavalier-Barsoum, K. Ma, M. Santos Dutra, Y. Kaitoukov, B. Bahoric, N. Tomic, F. Dinelle, S. Enger, G. Batist, S. Yang, D. Laporta, P. Kavan, A. Sahai, D. Roberge, and D. Donath, Feasibility and safety of endoscopic ultrasound-guided diffusing alpha emitter radiation therapy for advanced pancreatic cancer: Preliminary data, Endosc Int Open **12**, E1085–E1091 (2024).
- ³⁶ B. Baker and A. Farmery, Inert gas transport in blood and tissues, Compr. Physiol. 1, 569–92 (2011).
- ³⁷ G. Heger, M. Dumančić, I. Luz, M. Vatarescu, N. Weizman, B. W. Miller, T. Cooks, and L. Arazi, First measurements of radon-220 diffusion in mice tumors, towards treatment planning in diffusing alpha-emitters radiation therapy, Medical Physics **51**, 5045–5058 (2024).
- ³⁸ Y. Nishri, M. Vatarescu, I. Luz, L. Epstein, M. Dumančić, S. Del Mare, R. B. Den, I. Kelson, Y. Keisari, and V. Domankevich, Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts, Front. Oncol. **12** (2022).
- ³⁹ B. W. Miller, S. J. Gregory, E. S. Fuller, H. H. Barrett, H. B. Barber, and L. R. Furenlid, The iQID camera: An ionizing-radiation quantum imaging detector, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment **767**, 146–152 (2014).
- ⁴⁰ J. J. Moré, The Levenberg-Marquardt algorithm: Implementation and theory, in *Numerical Analysis*, edited by G. A. Watson, pages 105–116, Berlin, Heidelberg, 1978, Springer Berlin Heidelberg.
- ⁴¹ L. Epstein, G. Heger, A. Roy, I. Gannot, I. Kelson, and L. Arazi, The low-LET radiation contribution to the tumor dose in diffusing alpha-emitters radiation therapy, Medical physics 51, 3020–3033 (2024).

- ⁴² Jaap de Vries (2024). barrel and pincushion lens distortion correction (https://www.mathworks.com/matlabcentral/fileexchange/37980-barrel-andpincushion-lens-distortion-correction), MATLAB Central File Exchange.
- ⁴³ J. Browaeys, Linear fit with both uncertainties in x and in y, online exchange, 2022.